Clinical Radiology
Volume 63, Issue 8 , Pages 856-863 , August 2008

Can FDG-PET be used to predict growth of stage I lung cancer?

  • M. Tann

      Affiliations

    • Department of Radiology, Indiana University School of Medicine, Indianapolis, USA
    • ,
  • K. Sandrasegaran

      Affiliations

    • Department of Radiology, Indiana University School of Medicine, Indianapolis, USA
    • Corresponding Author InformationGuarantor and correspondent: K. Sandrasegaran, Department of Radiology, Indiana University School of Medicine, 550 N. University Boulevard, Suite UH0279, Indianapolis, IN 46202, USA. Tel.: +1 (317) 274 8832; fax: +1 (317) 274 1848.
    • ,
  • H.T. Winer-Muram

      Affiliations

    • Department of Radiology, Richard L. Roudebush Veterans' Association Medical Center, Indianapolis, USA
    • ,
  • S.G. Jennings

      Affiliations

    • Department of Radiology, Indiana University School of Medicine, Indianapolis, USA
    • ,
  • M.E. Welling

      Affiliations

    • Department of Radiology, Indiana University School of Medicine, Indianapolis, USA
    • ,
  • J.W. Fletcher

      Affiliations

    • Department of Radiology, Indiana University School of Medicine, Indianapolis, USA

Received 23 May 2007 ,Revised 31 December 2007 ,Accepted 13 January 2008.

References 

  1. Mountain CF. Staging classification of lung cancer. A critical evaluation. Clin Chest Med. 2002;23:103–121
  2. Ginsberg R, Cox J, Green M, et al. Staging classification committee. Lung Cancer. 1997;17(Suppl. 1):S11–S13
  3. Ambrogi MC, Lucchi M, Dini P, et al. Percutaneous radiofrequency ablation of lung tumours: results in the mid-term. Eur J Cardiothorac Surg. 2006;30:177–183
  4. Hiraki T, Sakurai J, Tsuda T, et al. Risk factors for local progression after percutaneous radiofrequency ablation of lung tumours: evaluation based on a preliminary review of 342 tumours. Cancer. 2006;107:2873–2880
  5. Matsuoka T, Okuma T. CT-guided radiofrequency ablation for lung cancer. Int J Clin Oncol. 2007;12:71–78
  6. Usuda K, Saito Y, Sagawa M, et al. Tumour doubling time and prognostic assessment of patients with primary lung cancer. Cancer. 1994;74:2239–2244
  7. Winer-Muram HT, Jennings SG, Tarver RD, et al. Volumetric growth rate of stage I lung cancer prior to treatment: serial CT scanning. Radiology. 2002;223:798–805
  8. Jerusalem G, Hustinx R, Beguin Y, et al. PET scan imaging in oncology. Eur J Cancer. 2003;39:1525–1534
  9. Maisey MN. Overview of clinical PET. Br J Radiol. 2002;75:S1–S5
  10. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001;2:157–164
  11. Minn H, Joensuu H, Ahonen A, et al. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer. 1988;61:1776–1781
  12. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med. 1992;33:325–329
  13. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201–3206
  14. Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998;83:918–924
  15. Duhaylongsod FG, Lowe VJ, Patz EF, et al. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg. 1995;60:1348–1352
  16. Yankelevitz DF, Reeves AP, Kostis WJ, et al. Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation. Radiology. 2000;217:251–256
  17. Revel MP, Merlin A, Peyrard S, et al. Software volumetric evaluation of doubling times for differentiating benign versus malignant pulmonary nodules. AJR Am J Roentgenol. 2006;187:135–142
  18. Arai T, Kuroishi T, Saito Y, et al. Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group. Jpn J Clin Oncol. 1994;24:199–204
  19. Lindell RM, Hartman TE, Swensen SJ, et al. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology. 2007;242:555–562
  20. Patz EF, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology. 1993;188:487–490
  21. Gupta NC, Frank AR, Dewan NA, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology. 1992;184:441–444
  22. Knight SB, Delbeke D, Stewart JR, et al. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest. 1996;109:982–988
  23. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg. 1995;60:1573–1581
  24. Wahl RL, Quint LE, Greenough RL, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology. 1994;191:371–377
  25. Scott WJ, Schwabe JL, Gupta NC, et al. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg. 1994;58:698–703
  26. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255–3260
  27. Harpole DH, Herndon JE, Wolfe WG, et al. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 1995;55:51–56
  28. Apolinario RM, van d V, de Jong JS, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol. 1997;15:2456–2466
  29. Harpole DH, Richards WG, Herndon JE, et al. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg. 1996;61:1470–1476
  30. Weiss W. Tumor doubling time and survival of men with bronchogenic carcinoma. Chest. 1974;65:3–8
  31. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early lung cancer action project: overall design and findings from baseline screening. Lancet. 1999;354:99–105
  32. Lowe VJ, Hoffman JM, Delong DM, et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med. 1994;35:1771–1776
  33. Keyes JW. SUV: standard uptake or silly useless value?. J Nucl Med. 1995;36:1836–1839
  34. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?. J Nucl Med. 1994;35:1308–1312
  35. Bogot NR, Kazerooni EA, Kelly AM, et al. Interobserver and intraobserver variability in the assessment of pulmonary nodule size on CT using film and computer display methods. Acad Radiol. 2005;12:948–956
  36. Zhao B, Schwartz LH, Moskowitz CS, et al. Pulmonary metastases: effect of CT section thickness on measurement—initial experience. Radiology. 2005;234:934–939
  37. Petrou M, Quint LE, Nan B, et al. Pulmonary nodule volumetric measurement variability as a function of CT slice thickness and nodule morphology. AJR Am J Roentgenol. 2007;188:306–312

PII: S0009-9260(08)00098-6

doi: 10.1016/j.crad.2008.01.012

Clinical Radiology
Volume 63, Issue 8 , Pages 856-863 , August 2008

Article Tools

* Image Usage & Resolution